VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EBMT 2020 | EBMT 2020: cellular therapy day

Annalisa Ruggeri • 31 Aug 2020
EBMT 2020
CAR-T

Annalisa Ruggeri, MD, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, discusses cellular therapy, specifically the engineering of T-cells and the use of mesenchymal stem cells (MSCs) for treating graft-versus-host disease (GvHD). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Annalisa Ruggeri

2:26
abTCD haploidentical HSCT in pediatric AL: long-term outcomes
Annalisa Ruggeri • 7 Dec 2019
3:39
HSCT with T-cell add-back of rivogenlecleucel in acute leukemia
Annalisa Ruggeri • 7 Dec 2019
10:00
Graft failure after unmanipulated haplo-HSCT with PT-Cy in AML
Annalisa Ruggeri • 26 Aug 2020
2:00
Association of HLA matching with outcome of UD-HSCT: EBMT study
Annalisa Ruggeri • 7 Dec 2019
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals